Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease.

Satyaprakash Nayak Brinda Tammara Lutz O Harnisch

Published in: Drugs in R&D (2021)

The pharmacokinetics of rivipansel was well characterized by a two-compartment population pharmacokinetic model. Our results illustrate the important role of simulations in optimizing a potential drug dosing regimen for patients with sickle cell disease and progressive renal impairment.

Keyphrases

end stage renal disease
chronic kidney disease
multiple sclerosis
newly diagnosed
prognostic factors
peritoneal dialysis
molecular dynamics
risk assessment
patient reported
climate change